Percentage of total users who discontinued their contraceptive method either during clinical trials or everyday use, specifically due to adverse events (AEs) or worries about possible AEs.*
| Contraceptive | Discontinuation due to AEs (%) | Sample size (n) | Publication | |
| Men | Women | |||
| Injectable combination male contraceptive | 6.25 | 320 | Behre et al 20168 | |
| Depo-provera injection | 36.6 | 12 529 | Daniels et al 20139 | |
| Transdermal system | 25.8 | 5631 | Daniels et al 20139 | |
| COC | 22.71 | 45 021 | Daniels et al 20139 | |
| COC | 6.0 | 1056 | Yaz13 | |
| COC | 6.7 | 2837 | Yasmin12 | |
| COC | 4.0 | 1723 | Ortho Tri Cyclen-Lo11 | |
| Vaginal ring | 13 | 2501 | NuvaRing17 | |
*The data on discontinuation from everyday use was measured over a 4-year period in the United States.
AE, adverse event; COC, combined oral contraceptive.